Raymond James Financial Inc. Purchases 12,619 Shares of Humana Inc. $HUM

Key Points

• Raymond James Financial Inc. increased its stake in Humana Inc. by 12.0%, acquiring an additional 12,619 shares, bringing its total holdings to approximately 117,932 shares valued at $31.2 million.
• Humana reported a 9.6% increase in quarterly revenue year-over-year, totaling $32.39 billion, although its earnings per share missed analysts' expectations.
• The company announced a quarterly dividend of $0.885 per share, which will be paid on October 31st, representing an annualized yield of 1.2%.

Raymond James Financial Inc. lifted its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 12.0% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 117,932 shares of the insurance provider's stock after acquiring an additional 12,619 shares during the quarter. Raymond James Financial Inc. owned approximately 0.10% of Humana worth $31,205,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Cary Street Partners Investment Advisory LLC increased its holdings in Humana by 63.9% in the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock valued at $31,000 after purchasing an additional 46 shares during the last quarter. Riverview Trust Co bought a new stake in Humana in the first quarter valued at about $34,000. Garde Capital Inc. bought a new stake in Humana in the first quarter valued at about $36,000. Zions Bancorporation National Association UT bought a new stake in Humana in the first quarter valued at about $37,000. Finally, Whipplewood Advisors LLC increased its holdings in Humana by 639.1% in the first quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider's stock valued at $45,000 after purchasing an additional 147 shares during the last quarter. Institutional investors own 92.38% of the company's stock.

Humana Stock Up 1.9%

NYSE:HUM opened at $300.0120 on Friday. Humana Inc. has a 1 year low of $206.87 and a 1 year high of $382.72. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. The stock has a market cap of $36.08 billion, a price-to-earnings ratio of 23.02, a PEG ratio of 1.76 and a beta of 0.44. The stock has a 50-day moving average price of $248.58 and a two-hundred day moving average price of $253.48.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The business had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. During the same period in the previous year, the firm posted $6.96 earnings per share. The firm's revenue was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, equities analysts expect that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend is Friday, September 26th. Humana's dividend payout ratio is currently 27.17%.

Analyst Ratings Changes

A number of equities research analysts recently commented on HUM shares. Truist Financial dropped their price objective on Humana from $280.00 to $260.00 and set a "hold" rating for the company in a report on Wednesday, July 16th. Piper Sandler dropped their price objective on Humana from $288.00 to $272.00 and set a "neutral" rating for the company in a report on Thursday, July 31st. Barclays set a $275.00 price objective on Humana and gave the company an "equal weight" rating in a report on Thursday, July 31st. Wells Fargo & Company dropped their price objective on Humana from $348.00 to $344.00 and set an "overweight" rating for the company in a report on Thursday, August 14th. Finally, Oppenheimer upped their price objective on Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a report on Thursday, May 1st. Seven investment analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $283.29.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.